ArticleSAGE open medical case reports2025
The sequential therapy for non-infectious scleritis: A case report.
Article in SAGE open medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Update on Therapy for Non-Infectious Scleritis.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Emerging therapeutic targets in non-infectious uveitis and scleritis.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scleritis results from an inflammatory response in the sclera and can be associated with a variety of infectious and non-infectious ocular and systemic diseases. It can cause vision loss, uveitis, high intraocular pressure and other complications, resulting in poor prognosis. There are no reports of non-infectious scleritis in children. Herein, we describe a case of sequential tocilizumab treatment on tofacitinib in a child with non-infectious scleritis. Extensive examinations ruled out the cause of infection, and the previous conventional glucocorticoid treatment was effective, but the disease recurred during drug reduction. Tocilizumab and tofacitinib successfully cured the patient, glucocorticoids were stopped, and all drugs were stopped 2 years later. This report provides a new diagnosis and treatment method for clinicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.